Hostname: page-component-8448b6f56d-wq2xx Total loading time: 0 Render date: 2024-04-25T05:18:30.306Z Has data issue: false hasContentIssue false

Legal Epidemiology: The Science of Law

Published online by Cambridge University Press:  01 January 2021

Abstract

The importance of legal epidemiology in public health law research has undoubtedly grown over the last five years. Scholars and practitioners together have developed guidance on best practices for the field, including: placing emphasis on transdisciplinary collaborations; creating valid, reliable, and repeatable research; and publishing timely products for use in decision-making and change. Despite the energy and expertise researchers have brought to this important work, they name significant challenges in marshalling the diverse skill sets, quality controls, and funding to implement legal epidemiology activities. The Centers for Disease Control and Prevention (CDC) has worked to develop cross-cutting research and translation on issues of national priority in legal epidemiology, and has explored ways to overcome some of these challenges. As such, this article describes a case study of the use of law to characterize states' prior authorization policies regarding medication used to treat attention-deficit/hyperactivity disorder (ADHD), a central component of a broader effort to improve behavior therapy options for young children with ADHD. This article highlights the types of legal epidemiology work we have undertaken, the application of this work to an emerging public health problem, and the lessons learned in creating impactful research for the field.

Type
Symposium Articles
Copyright
Copyright © American Society of Law, Medicine and Ethics 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Frieden, T. R., “A Framework for Public Health Action: The Health Impact Pyramid,” American Journal of Public Health 100, no. 4 (2010): 590-595.CrossRefGoogle Scholar
Pepin, D. et al., “Collaborating for Health: Health in All Policies and the Law,” Journal of Law, Medicine & Ethics 45, no. 1, Supp. (2017): 60-64.CrossRefGoogle Scholar
Presley, D. et al., Resources for Policy Surveillance, Technical Standards for Policy Surveillance and Legal Datasets: Report of a Delphi Process, available at <http://publichealthlawre-search.org/sites/default/files/uploaded_images/CombinedYear1Report_Feb2015.pdf> (last visited January 23, 2017).+(last+visited+January+23,+2017).>Google Scholar
Burris, S. et al., “A Transdisciplinary Approach to Public Health Law: The Emerging Practice of Legal Epidemiology,” Annual Review of Public Health 37 (2016): 135-148.CrossRefGoogle Scholar
Burris, S. et al., “Policy Surveillance: A Vital Public Health Practice Comes of Age,” Journal of Health Politics, Policy and Law 41, no. 6 (2016): 1061-1083.CrossRefGoogle Scholar
Burris, S. et al., “Moving from Intersection to Integration: Public Health Law Research and Public Health Systems and Services Research,” The Milbank Quarterly 90, no. 2 (2012): 375-408.CrossRefGoogle Scholar
Agency for Healthcare Research and Quality, Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-Term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment (2011), available at <https://effectivehealthcare.ahrq.gov/ehc/products/191/814/CER44_ADHD_ExecSumm_20111021.pdf> (last visited January 23, 2017).+(last+visited+January+23,+2017).>Google Scholar
Visser, S. N. et al., “Trends in the Parent-Report of Health Care Provider-Diagnosed and Medicated Attention-Deficit/Hyperactivity Disorder: United States, 2003–2011,” Journal of the American Academy of Child & Adolescent Psychiatry 53, no. 1 (2014): 34-46.e2.CrossRefGoogle Scholar
Visser, S. N. et al., “Vital Signs: National and State-Specific Patterns of Attention Deficit/Hyperactivity Disorder Treatment among Insured Children Aged 2-5 Years - United States, 2008-2014,” Morbidity and Mortality Weekly Report 65, no. 17 (2016): 443-450.CrossRefGoogle Scholar
Charach, A. et al., “Interventions for Preschool Children at High Risk for ADHD: A Comparative Effectiveness Review,” Pediatrics 131, no. 5 (2013): e1584-e1604.CrossRefGoogle Scholar
American Academy of Pediatrics, “ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,” Pediatrics 128, no. 5 (2011): 1007-1022.CrossRefGoogle Scholar
See supra note 13.Google Scholar
Anderson, E. et al., “Measuring Statutory Law and Regulations for Empirical Research,” in Wagenaar, A. C., and Burris, S., eds., Public Health Law Research: Theory and Methods (San Francisco, CA: Jossey-Bass, 2013): at 237-260.Google Scholar
Hulkower, R. et al., “50-State Assessment of Medicaid Prior-Authorization Policies for Medication Treatment of ADHD in Young Children” (forthcoming 2017).Google Scholar
Prior Authorization Policies for Pediatric ADHD Medication Prescriptions, “LawAtlas: The Policy Surveillance Portal,” available at <http://lawatlas.org/datasets/adhd-prior-authorization-policies> (last visited February 16, 2017).+(last+visited+February+16,+2017).>Google Scholar